

Stuart A. Williams

PARTNER

Litigation

swilliams@wsgr.com
212-497-7705

FOCUS AREAS

Arbitration
Global Generics
Litigation

HIGHLIGHTS

- **Former Mylan Pharmaceuticals Executive**
Stuart previously served as chief legal officer of leading generic and specialty pharmaceutical company Mylan Pharmaceuticals, where he focused on intellectual property counseling and litigation.
- **Collaborative Global Generics Focus**
With a focus on the firm's global generics practice, Stuart works closely with a variety of practice areas, including litigation, intellectual property, antitrust, FDA/regulatory, corporate, and mergers and acquisitions.

EXPERIENCE

Stuart A. Williams is a partner at Wilson Sonsini Goodrich & Rosati, where he focuses on the global generics practice, working closely with many different practice areas across the firm, including litigation, intellectual property, antitrust, FDA/regulatory, corporate, and mergers and acquisitions.

Prior to joining the firm, Stuart served as chief legal officer of Mylan Pharmaceuticals, one of the world's leading generic and specialty pharmaceutical companies. In this position, Stuart reported directly to the chief executive officer and handled all legal issues affecting both the parent company and its subsidiaries. While he focused on intellectual property counseling and litigation, other key responsibilities included management of and participation in scores of complex trials and appeals, antitrust counseling, arbitration, negotiating and drafting the full spectrum of company agreements, and managing regulatory issues of first impression and government inquiries.

More broadly, Stuart assisted the company's senior management with strategic planning that encompassed the unique combination of product development, litigation tactics, government regulation, partnerships, licensing arrangements, and mergers and acquisitions. He also held oversight of Mylan's human resources function and served as secretary of its board of directors.

Before joining Mylan, Stuart was Of Counsel at DKW Law Group in Pittsburgh. Prior to that, he was a partner at Eckert Seamans Cherin & Mellott, providing outside counsel to clients in a wide variety of industries, including pharmaceuticals, gaming, real estate, manufacturing, sports, entertainment, communications, and healthcare. He also served as the firm's managing director and a member of its board of directors.

Stu previously was involved in several successful business efforts. He served as president of the Washington Trotting Association and Meadows Real Estate, where he was responsible for the day-to-day operations of a racing and gaming facility that was then the largest employer in Washington County, Pennsylvania. Stu also served as a principal advisor to the chairperson and chief executive

officer of SG Rehabilitation/SG Speech Associates, a provider of speech, occupational, and physical rehabilitation services to nursing homes, hospitals, and schools.

CREDENTIALS

Education

- J.D., Georgetown University Law Center, 1978
Member, Phi Delta Phi honor society; Editor, The Tax Lawyer
- B.A., Pennsylvania State University, 1975
Summa Cum Laude, Phi Beta Kappa

Admissions

- State Bar of Pennsylvania

INSIGHTS

Select Publications

- Co-author, "FDA's Proposed Rules to Address Inaccurate Orange Book Use Codes May Shorten Approval Timelines for Select 505(b)(2) and Generic Drugs," *Generic Pharma 2.0*, July 15, 2015
- Co-author with D.M. Hoffmeister, V. Norviel, J. Guise, P. Munson, D. Carsten, R. Torczon, P. Girinath, and C. Andres, "A Good Opinion Is Worth Its Weight in Gold: Take-Home Lessons for Generic Pharmaceutical Companies to Minimize the Risk of Fee Shifting and Sanctions in the Wake of *Highmark* and *Octane Fitness*," *Generic Pharma Litigator*, January 28, 2015
- Co-author with D. Hoffmeister, V. Norviel, J. Guise, P. Munson, D. Carsten, R. Torczon, C. Andres, and P. Girinath, "Takeaways for Generics After *Octane* and *Highmark*," *Law360*, September 15, 2014